Which Treatments Lead Neuropathic Pain Care?
METHODOLOGY:
Researchers conducted systematic searches in Embase, PubMed, the International Clinical Trials Registry, and ClinicalTrials.gov.
A total of 313 trials (284 pharmacologic and 29 neuromodulation studies) were analysed, comprising 48,789 adults treated for neuropathic pain.
The primary efficacy outcome was the proportion of participants achieving at least 50% or 30% reduction in baseline pain intensity or moderate pain relief, and the primary safety outcome was the number of participants who withdrew from treatment due to adverse events.
Nine neuromodulation and 89 pharmacologic interventions were assessed. For each treatment, risk differences were used to determine the number needed to treat (NNT) and the number needed to harm (NNH).
TAKEAWAY:
Strong recommendations were made for the use of TCAs (NNT, 4.6; NNH, 17.1; moderate certainty of evidence), alpha-2-delta ligands (NNT, 8.9; NNH, 26.2; moderate certainty of evidence), and SNRIs (NNT, 7.4; NNH, 13.9; moderate certainty of evidence) as first-line treatments.
Weak recommendations were made for the use of capsaicin 8% patches (NNT, 13.2; NNH, 1129.3; moderate certainty of evidence), capsaicin cream (NNT, 6.1; NNH, 18.6; very low certainty of evidence), and lidocaine 5% plasters (NNT, 14.5; NNH, 178.0; very low certainty of evidence) as second-line treatments.
Furthermore, weak recommendations were made for the use of botulinum toxin type A (NNT, 2.7; NNH, 216.3; moderate certainty of evidence), rTMS (NNT, 4.2; NNH, 651.6; low certainty of evidence), and opioids (NNT, 5.9; NNH, 15.4; low certainty of evidence) as third-line treatments.
IN PRACTICE:
"The recommendations highlight the need for shared decision making, prioritising patient autonomy and preferences when tailoring treatment strategies. Health-care professionals should adapt these guidelines to their specific contexts, accounting for the cost, accessibility, and feasibility of treatments," the authors wrote, emphasizing the need for further "placebo-controlled or sham-controlled trials done over clinically relevant timeframes."
SOURCE:
This study was led by Nadia Soliman, PhD, Imperial College London, London, England, and Xavier Moisset, MD, Université Clermont Auvergne, CHU Clermont-Ferrand, Clermont-Ferrand, France. It was published online in the May 2025 issue of The Lancet Neurology .
LIMITATIONS:
This study was limited by potentially selective decision-making and heterogeneity in trial design, outcome measures, and reporting, thereby reducing precision. Crossover designs and inconsistent placebo responses may have contributed to changes in treatment effect estimates. Several studies lacked dose-response data, detailed adverse event reporting, and long-term follow-up, constraining safety assessments.
DISCLOSURES:
This study was funded by the NeuPSIG committee and ERA-NET Neuron. Several authors reported having various ties with various sources. Details are provided in the original article.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indianapolis Star
6 days ago
- Indianapolis Star
Brinton Vision Releases 2025 Update on LASIK Safety Backed by Landmark Clinical Studies
As questions about LASIK eye surgery continue to surface in public discussions and media coverage, Brinton Vision has released a new in-depth article titled 'I s LASIK Safe? A 2025 Update Backed By New Clinical Studies ', providing timely insight and expert analysis on the procedure's long-term safety and effectiveness. Drawing from two major 2024–2025 studies, the article addresses common concerns, presents compelling data, and reinforces why LASIK remains one of the safest and most successful elective surgeries available today. The team at Brinton Vision emphasizes that patient safety has always been and continues to be the foundation of its care philosophy. As a practice specializing exclusively in vision correction, Brinton Vision leverages the latest diagnostic tools, advanced laser technology, and a deeply personalized screening process to ensure optimal outcomes. In light of emerging research, the 2025 update was developed to give potential patients and healthcare journalists a clear, evidence-based view of LASIK's safety record, the factors that contribute to positive results, and how modern techniques mitigate risk. One of the most significant updates covered in the article is a 2024 meta-analysis published in the Journal of Advanced Trends in Medical Research, which analyzed 26 high-quality studies involving 1,879 LASIK patients and over 2,000 controls. The findings confirmed that LASIK offers statistically significant improvements in uncorrected visual acuity for patients with myopia and astigmatism. Importantly, complication rates were extremely low. A second study published in 2025 via PubMed reviewed 95 LASIK studies and reported that 88.3% of myopic patients achieved 20/20 uncorrected distance vision. Even more promising, topography-guided LASIK (TG-LASIK)—a method used at Brinton Vision—achieved 20/20 vision in 91.8% of patients, underscoring the value of precision technology and tailored treatment plans. The article further explains that LASIK complications are not only rare but typically minor and temporary. These include dry eye symptoms, glare, and halos—issues that most patients experience only during the early healing period. The 2025 literature review reported that sight-threatening complications such as flap folds occurred in just 0.73% of cases, and the most serious risks, like infection or post-LASIK ectasia, affected only 0.07% of eyes. These statistics mirror Brinton Vision's internal outcomes, which consistently demonstrate a low rate of complications due to the clinic's advanced screening methods and high clinical standards. Every candidate undergoes an in-depth assessment using tools such as wavefront-guided diagnostics and corneal topography to determine eligibility and reduce risk. Dr. Jason Brinton, founder of Brinton Vision and a board-certified refractive surgeon, believes this kind of research is vital for empowering patients with clear, credible information. 'LASIK has been studied for decades and continues to prove itself as one of the most successful elective procedures in medicine,' Dr. Brinton says. 'What makes the difference is not just the technology, but the experience of the surgeon and the quality of the evaluation process. We don't take shortcuts. Our goal is to make sure that every person we treat is a good candidate and receives the highest standard of care available.' In addition to safety, the article explores how LASIK compares to glasses and contact lenses. While corrective lenses can temporarily improve vision, they do not address the underlying refractive error or eliminate the need for daily maintenance. Contact lenses, in particular, carry their own risks, including an increased likelihood of corneal infection. Brinton Vision patients often report a sense of freedom and confidence after LASIK, describing improvements in everyday activities such as driving, working, and exercising without the hassle of glasses or contacts. Many call it life-changing, a sentiment backed by the 2025 PubMed study that found 92.6% of patients were satisfied with their results, and 99% would recommend LASIK to others. One of the major takeaways from the 2025 article is the clear connection between surgical outcomes and the combination of advanced technology and clinical experience. LASIK at Brinton Vision is performed using state-of-the-art femtosecond and excimer lasers, which are guided by real-time imaging systems and customized treatment maps based on the patient's corneal structure and visual profile. These tools help surgeons achieve a higher level of precision and reduce the margin for error. The practice's commitment to ongoing education, compliance with FDA regulations, and integration of the latest ophthalmology research reinforces its position as a national leader in refractive surgery. Reporters covering the evolving landscape of elective vision correction will find the article's analysis of recent studies and real-world clinical data especially relevant. With LASIK often misunderstood in the broader conversation around eye health, Brinton Vision's update provides clarity and context, grounded in research and firsthand surgical experience. By publishing this comprehensive safety overview, the practice hopes to educate not only potential patients but also journalists and referring providers who want to stay current on one of the most commonly performed eye surgeries in the United States. Brinton Vision invites media inquiries and welcomes the opportunity to provide additional data, commentary, or expert interviews with Dr. Brinton regarding LASIK safety, current trends in refractive surgery, and the future of vision correction. The full article, 'Is LASIK Safe? A 2025 Update Backed By New Clinical Studies', is available now on the Brinton Vision website and serves as a resource for patients who want to understand their options and make informed decisions. The post Brinton Vision Releases 2025 Update on LASIK Safety Backed by Landmark Clinical Studies appeared first on DA80 Hub.
Medscape
01-08-2025
- Medscape
Chemotherapy Linked to Brain Atrophy in Breast
Patients with breast cancer who undergo chemotherapy may face an increased risk for brain atrophy and cognitive decline, new findings from a pilot study suggested. Memory problems in patients with cancer may not stem solely from stress or anxiety related to their diagnosis but could reflect underlying changes in brain structure, study investigator Paul Edison, PhD, MPhil, professor of neuroscience and clinical professor of neurology at Imperial College London, London, England, told Medscape Medical News . While the findings suggest that chemotherapy may contribute to neuronal damage, the researchers noted that many aspects of the relationship between treatment and brain changes remain unclear. Edison highlighted three key areas that require further investigation — uncovering the mechanisms driving brain atrophy, determining the proportion of patients affected, and identifying effective prevention strategies. Another investigator on the study, Laura Kenny, MD, PhD, associate professor and consultant medical oncologist at Imperial College London, noted that the issue has received limited attention to date but expressed hope that the findings will raise awareness and encourage further research, given its clinical importance. The findings were presented on July 29 at the Alzheimer's Association International Conference (AAIC) 2025. Investigating Cognitive Impact Advances in chemotherapeutic agents have improved survival rates in patients with cancer. However, challenges persist regarding the long-term impact of these drugs. Chemotherapy-associated cognitive impairment, often referred to as 'brain fog' or 'chemobrain,' affects approximately one third of patients with breast cancer following treatment. While cognitive decline resolves within 12 months for some patients, others experience persistent effects that may elevate the risk for neurodegenerative conditions, Edison explained. To evaluate the impact of chemotherapy on the brain, investigators studied 328 women with nonmetastatic breast cancer who had undergone chemotherapy within the past 12 months. Patients received either anthracycline — a drug derived from the Streptomyces peucetius bacterium — or taxanes such as docetaxel and paclitaxel, both commonly used in breast cancer treatment, or a combination of these agents. In addition, some patients may also have had hormone therapy at some point during treatment, said Kenny. Participants completed neurocognitive prescreening tests every 3 months using a specialized artificial intelligence-driven platform, allowing them to take detailed memory assessments online from home. Among those prescreened, 18 individuals with lower neurocognitive scores (mean age, approximately 55 years) and 19 cognitively normal control individuals without breast cancer (mean age, approximately 67 years) underwent comprehensive, in-person, neurocognitive evaluations and MRI scans. Researchers analyzed the scans using region of interest (ROI) and voxel-based morphometry (VBM), which uses sophisticated computer software, to assess grey matter volumes and surface areas. The ROI analysis revealed significant reductions in gray matter volume (measured in mm3) and surface area (measured in mm2) among patients experiencing chemobrain, particularly affecting the isthmus cingulate and pars opercularis, with changes extending into the orbitofrontal and temporal regions. Significant Atrophy The VBM analysis confirmed significant atrophy in the frontal, parietal, and cingulate regions of patients with chemobrain compared with control individuals ( P < .05). Edison noted that this pattern overlaps with brain changes typically observed in Alzheimer's disease and vascular cognitive impairment. For both analyses, 'we demonstrated there is some amount of shrinkage in the brain among patients with chemobrain.' he said. 'The fact that controls are older means the results are even more significant as there's more brain atrophy as people age.' Some of the affected brain regions may be linked to impaired memory, a hallmark of Alzheimer's disease, but Edison cautioned that given the small sample size this finding should be interpreted with caution. While the analysis demonstrated overall lower brain volumes in patients with 'chemobrain' compared with controls, Edison emphasized that this finding reflects a single time point and does not indicate brain shrinkage over time. Other events, including stroke — can also cause brain changes. Edison highlighted the importance of determining the significance of these brain changes, how they affect patients and whether they can be prevented. In-person neurocognitive testing revealed significantly reduced semantic and verbal fluency, as well as lower Mini-Mental State Examination scores in patients with chemobrain. Edison noted that these results support the MRI findings. The team plans to follow patients to track brain changes and memory recovery, Kenny said. While patients with breast cancer are a common focus, the researchers intend to expand the study to other cancers in both men and women, said Kenny. Anecdotally, many patients report memory problems during chemotherapy, she added. Based on discussions with her oncology colleagues, Kenny noted that many patients anecdotally report experiencing memory problems during chemotherapy. More Research Needed Commenting for Medscape Medical News , Rebecca M. Edelmayer, PhD, vice president, Scientific Engagement, at the Alzheimer's Association, said the research may help shed light on why women are more likely to develop dementia than men. For years now, experts have been trying to figure out what puts women at higher risk for AD and other dementias, said Edelmayer. 'We still don't understand whether this involves biologically driven risk factors or socially driven risk factors.' Research linking treatments for other health conditions to increased memory problems may offer some clues, she noted, suggesting a potential avenue for further investigation into the intersection of chemotherapy and neurodegenerative diseases such as Alzheimer's. However, Edelmayer emphasized that this line of research is still in its infancy. Much more work is needed to determine whether there is a direct cause-and-effect relationship with specific chemotherapy drugs, and whether some patients may already be predisposed or at higher risk for cognitive decline, she said. Also commenting for Medscape Medical News , Eric Brown, MD, associate scientist and associate chief of geriatric psychiatry at the Centre for Addiction and Mental Health in Toronto, Ontario, Canada, raised concerns about the study's design. One issue, he noted, is that the researchers did not image all patients who received chemotherapy but instead selected those with the most significant cognitive impairment. As a result, the findings may not have reflected outcomes in the average post-chemotherapy patients but rather represent the most severely affected subgroup. Brown also pointed out that the study did not clarify whether this subgroup had comorbid conditions. It's possible, he said, that some individuals may have had Alzheimer's disease or other forms of dementia unrelated to chemotherapy. He agreed that tracking longitudinal changes in both cognitive scores and neuroimaging — comparing patients who receive chemotherapy with those who do not — would be a valuable next step.
Yahoo
30-07-2025
- Yahoo
More Proof You Don't Need 10,000 Steps a Day—a New Study Reveals the Actual Sweet Spot
Key Takeaways Walking 7,000 steps daily is linked to significantly lower risks of death and heart disease—making it a realistic and effective alternative to the 10,000-step goal. Younger adults benefit most around 5,400 steps per day, while for older adults, more steps continue to bring more health benefits with no clear upper limit. Daily walking—especially over time—is shown to reduce symptoms of depression and anxiety, particularly in older walkers, listen up: you probably don't have to hit 10,000 steps a day to be physically active and enjoy the benefits. According to a new study published in The Lancet, a peer-reviewed medical journal, it is possible to reap the health benefits of daily walks without specifically aiming for a 10,000-step goal—in fact, you could achieve the same results by walking between 5,000 to 7,000 steps per day instead. 'Although 10,000 steps per day can still be a viable target for those who are more active, 7,000 steps per day is associated with clinically meaningful improvements in health outcomes and might be a more realistic and achievable target for some,' the study notes. Read on to learn more—including how and why a decreased number of steps can be just as effective. Related: 13 Unexpected Health Benefits of Walking and How to Make a Habit of It Why You Don't Need 10,000 Steps a Day The researchers conducted a systematic review and meta-analysis of studies on PubMed and EBSCO that examined the relationship between daily steps (measured through a tracking device) and health outcomes among adults. What they found was that 7,000 steps a day—compared to 2,000—was associated with a 47% lower risk of all-cause mortality, a 25% lower risk of cardiovascular disease, and a 47% lower risk of cardiovascular disease mortality. The research also found that the number of steps you need per day might depend on your age. The link between daily steps and all-cause mortality was non-linear for younger adults with an inflection point of 5,410 steps per day. However, for older adults, there was an inverse linear relationship between number of steps and all-cause mortality. What this means is that for younger adults, about 5,400 steps is the sweet spot for reaping the benefits of daily walking. For older adults, it seems the more steps you take, the better—and there's no clear limit where the benefits level off. It's also no surprise that the research found an inverse linear relationship between the number of steps walked each day and the onset of depressive symptoms. The researchers specifically refer to one Taiwanese study that found a 5% reduced rate of depressive symptoms when people walked 1,000 more steps each day for at least two years. Overall, however, the study concluded that 7,000 steps compared to 10,000 steps did not make a statistically significant difference when it came to cardiovascular health and chronic disease prevention. So the next time you lace up your running shoes, remember that you don't always have to hit that 10,000-step goal. Related: Rucking Is the No-Equipment Way to Get the Most From Your Daily Walk—Here's How to Get Started Read the original article on Real Simple
